These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 24422792

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
    Luu M, Boone SL, Patel J, Sullivan P, Rademaker AW, Balagula Y, Lacouture ME.
    Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
    Wnorowski AM, de Souza A, Chachoua A, Cohen DE.
    Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
    [Abstract] [Full Text] [Related]

  • 9. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
    Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T.
    J Dermatol; 2020 Feb; 47(2):121-127. PubMed ID: 31803963
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
    Lee Y, Shim HS, Park MS, Kim JH, Ha SJ, Kim SH, Cho BC.
    Clin Cancer Res; 2012 Mar 15; 18(6):1760-8. PubMed ID: 22271877
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, Verweij J, Rowinsky EK, Krueger JG.
    Eur J Cancer; 2010 Jul 15; 46(11):2010-9. PubMed ID: 20621734
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Xerosis and pruritus as major EGFRI-associated adverse events.
    Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, Kaptein AA.
    Support Care Cancer; 2016 Feb 15; 24(2):513-521. PubMed ID: 26111953
    [Abstract] [Full Text] [Related]

  • 19. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
    Cignola S, Gonella S, Alessandra B, Palese A.
    Eur J Oncol Nurs; 2016 Feb 15; 20():133-9. PubMed ID: 26187661
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.